BG102880A - Катионни вирозоми като системи за трансфер на генетичен материал - Google Patents

Катионни вирозоми като системи за трансфер на генетичен материал

Info

Publication number
BG102880A
BG102880A BG102880A BG10288098A BG102880A BG 102880 A BG102880 A BG 102880A BG 102880 A BG102880 A BG 102880A BG 10288098 A BG10288098 A BG 10288098A BG 102880 A BG102880 A BG 102880A
Authority
BG
Bulgaria
Prior art keywords
virosomes
cation
preparation
transfer systems
genetic materials
Prior art date
Application number
BG102880A
Other languages
English (en)
Inventor
Ernst WAELTI
Reinhard Glueck
Peter Klein
Original Assignee
Nika Health Products Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Limited filed Critical Nika Health Products Limited
Publication of BG102880A publication Critical patent/BG102880A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретението се отнася до положително заредени вирозоми за ефективно доставяне на генетичен материал до намиращи се в покой или пролифериращи клеткина бозайници in vitro и in vivo. Мембраната на вирозома съдържа катионни и/или поликатионни липиди,най-малко един вирусен слят пептид и, за предпочитане, най-малко един клетъчно-специфичен маркер, избран от групата, състояща се от моноклонални антитела, фрагменти на антитела F(ab')2 и Fab', цитокини и фактори на растежа, за селективна детекция и залепване на клетки мишени. Изобретението се отнася също до метод за получаването на нови вирозоми идо тяхното приложение, по-специално до получаването на фармацевтични състави за лечение на рак или левкемия.
BG102880A 1996-05-08 1998-10-29 Катионни вирозоми като системи за трансфер на генетичен материал BG102880A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08
PCT/EP1997/002268 WO1997041834A1 (en) 1996-05-08 1997-05-04 Cationic virosomes as transfer system for genetic material

Publications (1)

Publication Number Publication Date
BG102880A true BG102880A (bg) 1999-05-31

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102880A BG102880A (bg) 1996-05-08 1998-10-29 Катионни вирозоми като системи за трансфер на генетичен материал

Country Status (28)

Country Link
US (1) US6210708B1 (bg)
EP (1) EP0902682A2 (bg)
JP (1) JP2000509404A (bg)
KR (1) KR100536983B1 (bg)
CN (1) CN1271992C (bg)
AR (1) AR007054A1 (bg)
AU (1) AU710170B2 (bg)
BG (1) BG102880A (bg)
BR (1) BR9709224A (bg)
CA (1) CA2253561A1 (bg)
CO (1) CO4600638A1 (bg)
CZ (1) CZ299809B6 (bg)
EA (1) EA003130B1 (bg)
GT (1) GT199700058A (bg)
HR (1) HRP970234B1 (bg)
HU (1) HUP9901790A3 (bg)
ID (1) ID17934A (bg)
NO (1) NO327726B1 (bg)
NZ (1) NZ332666A (bg)
OA (1) OA10916A (bg)
PA (1) PA8429201A1 (bg)
PE (1) PE65198A1 (bg)
PL (1) PL199201B1 (bg)
SK (1) SK152698A3 (bg)
SV (1) SV1997000032A (bg)
TN (1) TNSN97080A1 (bg)
WO (1) WO1997041834A1 (bg)
ZA (1) ZA973885B (bg)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
WO1999012575A1 (en) * 1997-09-08 1999-03-18 Promega Corporation Method of in vivo transformation utilizing lipid vehicles
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
WO2001026628A1 (en) * 1999-10-08 2001-04-19 Nika Health Products Limited Cationic dosper virosomes
DE50002682D1 (de) * 1999-12-17 2003-07-31 Schott Glas Induktiv aktivierbare zündkapsel für insassen-rückhaltesysteme und prüfschaltung für diese zündkapsel
US20030139361A1 (en) * 2000-01-21 2003-07-24 Kazuhiro Yuda Drug for gene therapy
US20030021768A1 (en) * 2001-07-23 2003-01-30 Yuqiao Shen Viral mutants that selectively replicate in targeted human cancer cells
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
EA008497B1 (ru) * 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
EP1687017B1 (en) 2003-10-24 2013-03-06 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CN102026645B (zh) * 2006-09-15 2016-01-27 渥太华医院研究机构 溶瘤弹状病毒
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
WO2013050048A2 (en) * 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
WO2018060212A1 (en) 2016-09-27 2018-04-05 Camurus Ab Mixtures and formulations comprising an alkyl ammonium edta salt
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
DE69229703T2 (de) * 1991-05-08 2000-04-27 Schweiz Serum & Impfinst Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
ATE223701T1 (de) * 1994-05-31 2002-09-15 Inex Pharmaceutical Corp Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
PE65198A1 (es) 1998-10-16
JP2000509404A (ja) 2000-07-25
NO327726B1 (no) 2009-09-14
EA003130B1 (ru) 2003-02-27
CZ361498A3 (cs) 1999-03-17
KR100536983B1 (ko) 2006-06-29
AU2776697A (en) 1997-11-26
CN1271992C (zh) 2006-08-30
GT199700058A (es) 1998-10-29
NZ332666A (en) 2000-05-26
CA2253561A1 (en) 1997-11-13
SV1997000032A (es) 1998-03-27
WO1997041834A1 (en) 1997-11-13
EA199800992A1 (ru) 1999-06-24
PL329853A1 (en) 1999-04-12
AU710170B2 (en) 1999-09-16
KR20000010780A (ko) 2000-02-25
ID17934A (id) 1998-02-12
BR9709224A (pt) 1999-08-10
US6210708B1 (en) 2001-04-03
NO985137L (no) 1999-01-04
EP0902682A2 (en) 1999-03-24
PL199201B1 (pl) 2008-08-29
SK152698A3 (en) 1999-05-07
HRP970234B1 (en) 2002-04-30
HUP9901790A3 (en) 2010-11-29
CN1225007A (zh) 1999-08-04
CO4600638A1 (es) 1998-05-08
AR007054A1 (es) 1999-10-13
NO985137D0 (no) 1998-11-04
CZ299809B6 (cs) 2008-12-03
HUP9901790A2 (hu) 1999-08-30
ZA973885B (en) 1998-11-06
TNSN97080A1 (fr) 2005-03-15
PA8429201A1 (es) 2000-05-24
HRP970234A2 (en) 1998-06-30
OA10916A (en) 2003-02-21

Similar Documents

Publication Publication Date Title
BG102880A (bg) Катионни вирозоми като системи за трансфер на генетичен материал
Seyedin et al. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone.
Butler The nature and significance of osteopontin
Kasugai et al. Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter
Brunner et al. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
Guy et al. Coordinated action of IgE and a B-cell-stimulatory factor on the CD23 receptor molecule up-regulates B-lymphocyte growth.
Stadie et al. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP‐GalNAc: polypeptide N‐acetylgalactosaminyltransferase from milk or mammary carcinoma cells
CA2457632C (en) Identification and isolation of somatic stem cells and uses thereof
ZA953629B (en) Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
MX9702714A (es) Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral.
WO2002078598A3 (en) Peptides and antibodies to muc 1 proteins
EP0557418A4 (en) A -g(b)-type transforming growth factor
AU2002355970A1 (en) Identification and isolation of somatic stem cells and uses thereof
Schwartz-Albiez et al. Differential expression of annexins I and II in normal and malignant human mammary epithelial cells
GB9722320D0 (en) Human cell cycle checkpoint proteins
Okamura et al. Localization of a maturation-dependent epididymal sperm surface antigen recognized by a monoclonal antibody raised against a 135-kilodalton protein in porcine epididymal fluid
WO2000043499A3 (en) ANTI-TRANSFORMING GROWTH FACTOR BETA (TGF-β) TREATED STEM CELL COMPOSITION AND METHOD
Clark et al. Characterization of murine pregnancy decidua transforming growth factor b. I. Transforming growth factor b2-like molecules of unusual molecular size released in bioactive form
DE3751319T2 (de) VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN.
Imamoto-Sonobe et al. ATP-dependent association of nuclear proteins with isolated rat liver nuclei.
Davidson et al. Characterization of a signal peptide sequence in the cell-free translation product of sheep elastin mRNA
Bocchini et al. Glial fibrillary acidic protein and its encoding mRNA exhibit mosaic expression in a glioblastoma multiform cell line of clonal origin
Remold-O'Donnell Macrophage component gp160, a major trypsin-sensitive surface glycoprotein.
Mizuno et al. The osteoblastic MC3T3-E1 cells synthesized C-terminal propeptide of type I collagen, which promoted cell-attachment of osteoblasts
Chomette et al. Basaloid carcinoma of salivary glands, a variety of undifferentiated adenocarcinoma. Immunohistochemical study of intermediate filament proteins in 24 cases